Clinical Trial

Disease: Gastric Cancer, (NCT06098898)

Disease info:

Gastric (stomach) cancer is the fourth most common cancer worldwide. It begins in the stomach lining and can spread to lymph nodes or other organs. Most cases are adenocarcinomas, though rarer forms include gastrointestinal stromal tumours, carcinoid tumours, and lymphomas.

A key risk factor is infection with Helicobacter pylori, which can cause inflammation and ulcers. Other risks include a family history of stomach cancer, certain inherited genetic syndromes, smoking, heavy alcohol use, obesity, a high-salt diet, and exposure to industrial chemicals. Men and people of African American, Hispanic, or Asian descent face higher risk.


Early stages often produce few or no symptoms. When present, warning signs may include difficulty swallowing, stomach pain or discomfort, bloating after small meals, nausea or vomiting (sometimes with blood), blood in the stool, and unexplained weight loss. Because these symptoms can mimic common digestive issues, medical evaluation is important for accurate diagnosis.

Source: Gastric (Stomach) Cancer Symptoms & Stages | UPMC

Frequency:
There are around 21,000 new stomach cancer cases each year .
Official title:
Exploratory Study of NK510 Cell Therapy Combined With Monoclonal Antibody in the Treatment of Recurrent and Refractory Advanced Gastric Cancer
Who:
Sponsor:

Base Therapeutics (Shanghai) Co., Ltd.
 

Partners:

Shanghai 10th People's Hospital

Locations:

Shanghai, China

Shanghai Tenth People's Hospital, Shanghai, China

Study start:
Nov. 1, 2023
Enrollment:
9 participants
Gene editing method:
AccuBase® base editor
Type of edit:
Gene knockout and gene knock in
Gene:
Knockout of PD-1 and knock in of CD16
Delivery method:
- Ex-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Enrolling by invitation

Last updated: Sep. 22, 2025
close
Search CRISPR Medicine